| Genomic characterization of metastatic breast cancers F Bertucci, CKY Ng, A Patsouris, N Droin, S Piscuoglio, N Carbuccia, ... Nature 569 (7757), 560-564, 2019 | 633 | 2019 |
| Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer L Martinet, I Garrido, T Filleron, S Le Guellec, E Bellard, JJ Fournie, ... Cancer research 71 (17), 5678-5687, 2011 | 531 | 2011 |
| Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER) F André, T Bachelot, F Commo, M Campone, M Arnedos, V Dieras, ... The lancet oncology 15 (3), 267-274, 2014 | 457 | 2014 |
| Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ... Journal of clinical oncology 33 (9), 992-999, 2015 | 431 | 2015 |
| Mutational profile of metastatic breast cancers: a retrospective analysis C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ... PLoS medicine 13 (12), e1002201, 2016 | 395 | 2016 |
| TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma F Bertrand, A Montfort, E Marcheteau, C Imbert, J Gilhodes, T Filleron, ... Nature communications 8 (1), 2256, 2017 | 382 | 2017 |
| Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403-1410, 2017 | 369 | 2017 |
| Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, ... Annals of Oncology 27 (2), 281-286, 2016 | 334 | 2016 |
| DNA polymerase θ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability F Lemée, V Bergoglio, A Fernandez-Vidal, A Machado-Silva, MJ Pillaire, ... Proceedings of the National Academy of Sciences 107 (30), 13390-13395, 2010 | 241 | 2010 |
| Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in … S Gourgou-Bourgade, D Cameron, P Poortmans, B Asselain, D Azria, ... Annals of Oncology 26 (5), 873-879, 2015 | 236 | 2015 |
| Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network C Laurent, M Baron, N Amara, C Haioun, M Dandoit, M Maynadié, ... Journal of clinical Oncology 35 (18), 2008-2017, 2017 | 220 | 2017 |
| High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes L Martinet, S Le Guellec, T Filleron, L Lamant, N Meyer, P Rochaix, ... Oncoimmunology 1 (6), 829-839, 2012 | 215 | 2012 |
| Targeted therapy for patients with BRAF-mutant lung cancer results from the European EURAF cohort O Gautschi, J Milia, B Cabarrou, MV Bluthgen, B Besse, EF Smit, J Wolf, ... Journal of Thoracic Oncology 10 (10), 1451-1457, 2015 | 213 | 2015 |
| Frequency of brain metastases and multikinase inhibitor outcomes in patients with RET–rearranged lung cancers A Drilon, JJ Lin, T Filleron, A Ni, J Milia, I Bergagnini, V Hatzoglou, ... Journal of Thoracic Oncology 13 (10), 1595-1601, 2018 | 189 | 2018 |
| Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO) T Valentin, A Le Cesne, I Ray-Coquard, A Italiano, G Decanter, E Bompas, ... European journal of cancer 56, 77-84, 2016 | 172 | 2016 |
| CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics S Le Guellec, I Soubeyran, P Rochaix, T Filleron, A Neuville, I Hostein, ... Modern Pathology 25 (12), 1551-1558, 2012 | 168 | 2012 |
| Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial F Mosele, E Deluche, A Lusque, L Le Bescond, T Filleron, Y Pradat, ... Nature medicine 29 (8), 2110-2120, 2023 | 167 | 2023 |
| High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β–producing dendritic cells in human breast cancer L Martinet, T Filleron, S Le Guellec, P Rochaix, I Garrido, JP Girard The Journal of Immunology 191 (4), 2001-2008, 2013 | 163 | 2013 |
| CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients … A Gomez-Brouchet, C Illac, J Gilhodes, C Bouvier, S Aubert, ... Oncoimmunology 6 (9), e1331193, 2017 | 159 | 2017 |
| Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study A Benlyazid, J Thariat, S Temam, O Malard, C Florescu, O Choussy, ... Archives of Otolaryngology–Head & Neck Surgery 136 (12), 1219-1225, 2010 | 157 | 2010 |
benoit chaputUniversité Paul sabatierVerified email at chu-Toulouse.fr
